Literature DB >> 19138308

Transition probabilities and predictors of adherence in a California Medicaid population using antihypertensive and lipid-lowering medications.

Michael B Nichol1, Tara K Knight, Joanne Wu, Simon S K Tang, Spencer B Cherry, Joshua S Benner, Mohamed Hussein.   

Abstract

OBJECTIVES: To determine adherence rates, transition probabilities, and factors associated with transition from higher to lower adherence in antihypertensive (AH) and lipid-lowering (LL) medications.
METHODS: California Medicaid data (1995-2003) were used to identify hypertensive patients with prescriptions for both AH and LL medications. Proportion of days covered (PDC) was used to define three adherence classifications: fully adherent (FA, PDC >or= 0.8), partially adherent (PA, 0.2 <or= PDC < 0.8), and nonadherent (NA, PDC < 0.2). Annual transition matrices documented the probability of adherence status changes.
RESULTS: Only 13% of the 5943 patients were FA to both drugs at baseline. Patients who were FA (60%) or NA (84%) to both drugs had high probability of maintaining status at year two (Y2). Significant variables associated with a transition from adherent to NA at Y2 included African American race (odds ratio [OR] 1.5), other race groups (OR 1.2), lack of Medicare eligibility (OR 1.3), and initiating LL therapy of fibric acid derivatives (OR 1.3) or niacin (OR 1.8).
CONCLUSIONS: Patients FA or NA with both drugs at baseline were more likely to maintain their adherence status. Race, insurance coverage, and type of LL medication were significantly associated with transitioning from any adherence status to nonadherence. These findings may be useful in guiding cost-effectiveness analyses incorporating adherence estimates.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19138308     DOI: 10.1111/j.1524-4733.2008.00474.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  8 in total

1.  Combined estimation of disease progression and retention on antiretroviral therapy among treated individuals with HIV in the USA: a modelling study.

Authors:  Linwei Wang; Emanuel Krebs; Jeong E Min; W Christopher Mathews; Ank Nijhawan; Charurut Somboonwit; Judith A Aberg; Richard D Moore; Kelly A Gebo; Bohdan Nosyk
Journal:  Lancet HIV       Date:  2019-07-11       Impact factor: 12.767

2.  Prevalence and predictors of medication non-adherence among people living with multimorbidity: a systematic review and meta-analysis.

Authors:  Louise Foley; James Larkin; Richard Lombard-Vance; Andrew W Murphy; Lisa Hynes; Emer Galvin; Gerard J Molloy
Journal:  BMJ Open       Date:  2021-09-02       Impact factor: 3.006

3.  Individual patients hold different beliefs to prescription medications to which they persist vs nonpersist and persist vs nonfulfill.

Authors:  Colleen A McHorney; Abhijit S Gadkari
Journal:  Patient Prefer Adherence       Date:  2010-07-21       Impact factor: 2.711

4.  The Aston Medication Adherence Study: mapping the adherence patterns of an inner-city population.

Authors:  Christopher A Langley; Joseph Bush
Journal:  Int J Clin Pharm       Date:  2013-12-01

5.  Patterns of medication adherence in a multi-ethnic cohort of prevalent statin users diagnosed with breast, prostate, or colorectal cancer.

Authors:  Matthew P Banegas; Marc A Emerson; Alyce S Adams; Ninah S Achacoso; Neetu Chawla; Stacey Alexeeff; Laurel A Habel
Journal:  J Cancer Surviv       Date:  2018-10-18       Impact factor: 4.442

6.  HIV-1 disease progression during highly active antiretroviral therapy: an application using population-level data in British Columbia: 1996-2011.

Authors:  Bohdan Nosyk; Jeong Min; Viviane D Lima; Benita Yip; Robert S Hogg; Julio S G Montaner
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-15       Impact factor: 3.731

7.  Evaluation of the Effectiveness of a Patient-Centered Educational Mailer Designed to Improve Statin Adherence: A Pragmatic Trial.

Authors:  John W Nord; Alalia Berry; Barry Stults; Zachary Burningham; Srinivasan Beddhu
Journal:  EGEMS (Wash DC)       Date:  2017-01-23

8.  A comprehensive guidelines-based approach reduces cardiovascular risk in everyday practice: the VARO study.

Authors:  Tomáš Štulc; Věra Lánská; Michaela Šnejdrlová; Michal Vrablík; Martina Prusíková; Richard Češka
Journal:  Arch Med Sci       Date:  2016-12-29       Impact factor: 3.318

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.